COMPANY

AvantGen

HQ: San Diego, CA source · avantgen.com ↗ · West Coast

Keywords: antibody

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

26NIH grants

Timeline

Aug 11, 2025 Grant Government grant — SBIR: $574,272 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Feb 1, 2025 Grant Government grant — NIH N44: $1.5M (annual award, as published), announced Feb 1, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Aug 11, 2025 Government grant — SBIR: $574,272 (annual award, as published), announced Aug 11, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Feb 1, 2025 Government grant — NIH N44: $1.5M (annual award, as published), announced Feb 1, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 26

Annual award amounts. Total $12.9M.

Sep 9, 2024 NIH award 1R44CA291331-01 FY2024: $1,398,552 awarded for that fiscal year; activity R44 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. A novel approach for treating myelodysplastic synd source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024C00039-0-9999-1 FY2024: $592,751 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. DEVELOPMENT OF RA source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00047-0-9999-1 FY2021: $300,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIOAMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. DEVELOPMENT OF RA source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93021C00040-0-9999-1 FY2021: $356,021 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. DEVELOPMENT OF RA source ↗
2020 NIH contract (government contract; not a grant and not an investment round) 75N91020C00018-0-9999-1 FY2020: $1,995,852 awarded for that fiscal year; activity N44 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Development and source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 261201800041C-0-0-1 FY2018: $299,854 awarded for that fiscal year; activity N01 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. IGF::OT::IGF Topic 37 source ↗
Feb 23, 2016 NIH award 5R44DA035531-03 FY2016: $805,808 awarded for that fiscal year; activity R44 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Novel approach for developing antibody reagents to p source ↗
Aug 10, 2015 NIH award 1R43DK106946-01 FY2015: $224,670 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Developing a highly specific and sensitive glucagon source ↗
Feb 16, 2015 NIH award 4R44DA035531-02 FY2015: $756,189 awarded for that fiscal year; activity R44 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Novel approach for developing antibody reagents to p source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 261201500044C-0-0-1 FY2015: $999,996 awarded for that fiscal year; activity N44 (OTHER_NIH); PI FAN, XIAMON; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. IGF::OT::IGF RECOMBINA source ↗
Sep 3, 2014 NIH award 1R43DA038979-01 FY2014: $188,104 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Novel platform for isolation of rabbit monoclonal an source ↗
Aug 22, 2014 NIH award 1R43AG047694-01 FY2014: $224,528 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Discovery of novel Alzheimer's Disease-specific anti source ↗
Apr 22, 2013 NIH award 1R44DA035531-01 FY2013: $224,957 awarded for that fiscal year; activity R44 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Novel approach for developing antibody reagents to p source ↗
2013 NIH contract (government contract; not a grant and not an investment round) 261201300023C-0-0-1 FY2013: $199,987 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. TOPIC 319 PHASE I; RE source ↗
Aug 21, 2012 NIH award 5R43MH093995-02 FY2012: $341,965 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. A novel approach for developing GPCR subtype specifi source ↗
2012 NIH contract (government contract; not a grant and not an investment round) 261201200094C-0-0-1 FY2012: $747,441 awarded for that fiscal year; activity N44 (OTHER_NIH); PI n/a; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. OTHER FUNCTIONS SBIR PHASE II, source ↗
2012 NIH contract (government contract; not a grant and not an investment round) 268201200047C-0-0-1 FY2012: $990,779 awarded for that fiscal year; activity N44 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. OTHER FUNCTIONS - REC source ↗
2012 NIH contract (government contract; not a grant and not an investment round) 271201000019C-2-0-1 FY2012: $14,548 awarded for that fiscal year; activity N44 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. TAS::75 0893::TAS RENE source ↗
Sep 8, 2011 NIH award 1R43MH093995-01A1 FY2011: $349,719 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. A novel approach for developing GPCR subtype speci source ↗
Jul 19, 2010 NIH award 1R43HL103067-01 FY2010: $277,115 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Endothelial Lipase: a novel therapeutic target for H source ↗
2010 NIH contract (government contract; not a grant and not an investment round) 271201000019C-0-0-1 FY2010: $750,000 awarded for that fiscal year; activity N44 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. TAS::75 0893::TAS REN source ↗
2010 NIH contract (government contract; not a grant and not an investment round) 268201000042C-0-0-1 FY2010: $149,951 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. TAS::75 0872::TAS REC source ↗
2010 NIH contract (government contract; not a grant and not an investment round) 261201000072C-0-0-1 FY2010: $150,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. TAS::75 0849::TAS DEV source ↗
Mar 31, 2009 NIH award 1R43CA137884-01A1 FY2009: $158,025 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. Novel human anti-uPAR antibodies for the treatment source ↗
2009 NIH contract (government contract; not a grant and not an investment round) 271200900023C-0-0-1 FY2009: $200,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI WOODS, CATHERINE M; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. RENEWABLE CAPTO source ↗
Sep 5, 2008 NIH award 1R43NS061374-01A1 FY2008: $220,061 awarded for that fiscal year; activity R43 (SBIR); PI FAN, XIAOMIN; recipient as written: AVANTGEN, INC., SAN DIEGO, CA. A novel therapeutic antibody for treatment of isch source ↗